loading
前日終値:
$4.40
開ける:
$4.25
24時間の取引高:
3,789
Relative Volume:
0.09
時価総額:
$6.24M
収益:
$61,000
当期純損益:
$-5.46M
株価収益率:
-0.6636
EPS:
-6.54
ネットキャッシュフロー:
$-6.76M
1週間 パフォーマンス:
-2.47%
1か月 パフォーマンス:
-5.65%
6か月 パフォーマンス:
+27.65%
1年 パフォーマンス:
-22.08%
1日の値動き範囲:
Value
$4.17
$4.40
1週間の範囲:
Value
$4.17
$4.6499
52週間の値動き範囲:
Value
$3.03
$14.80

Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile

Name
名前
Titan Pharmaceuticals Inc De
Name
セクター
Healthcare (1175)
Name
電話
(650) 244-4990
Name
住所
400 OYSTER POINT BLVD, SAN FRANCISCO
Name
職員
4
Name
Twitter
@titanpharma
Name
次回の収益日
2024-06-28
Name
最新のSEC提出書
Name
TTNP's Discussions on Twitter

TTNP を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
TTNP
Titan Pharmaceuticals Inc De
4.34 6.24M 61,000 -5.46M -6.76M -6.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
523.14 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.39 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
548.00 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.53 28.51B 3.81B -644.79M -669.77M -6.24

Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2019-06-26 開始されました Maxim Group Buy
2017-11-10 ダウングレード ROTH Capital Buy → Neutral

Titan Pharmaceuticals Inc De (TTNP) 最新ニュース

pulisher
Jun 17, 2025

Lobe Sciences Secures $26M for Novel Chronic Cluster Headache Drug Development | LOBEF Stock News - Stock Titan

Jun 17, 2025
pulisher
Jun 10, 2025

Biotech to Environmental Services: Windtree's $12M Revenue Play in $85B Waste Management Market - Stock Titan

Jun 10, 2025
pulisher
Jun 04, 2025

Titan Medical (NASDAQ:TMDIF) Stock Price Down 2.4% – Here’s Why - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Merger Alert: Titan Pharmaceuticals Takes Major Step Toward TalenTec Combination with Critical SEC Filing - Stock Titan

Jun 03, 2025
pulisher
May 29, 2025

Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan

May 29, 2025
pulisher
May 27, 2025

Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan

May 27, 2025
pulisher
May 22, 2025

Biotech Rising Star Conduit Pharmaceuticals Gets Green Light for Nasdaq Capital Market Transfer - Stock Titan

May 22, 2025
pulisher
May 21, 2025

Petros Pharmaceuticals Faces NASDAQ Delisting Despite $10M Cash Position, Plans Appeal - Stock Titan

May 21, 2025
pulisher
May 21, 2025

Conduit Pharmaceuticals Secures Future on Nasdaq: Clears Both Bid Price and Equity Hurdles - Stock Titan

May 21, 2025
pulisher
May 16, 2025

Conduit Pharma Sets 15:1 Reverse Split: Shares Drop to 755,900 Starting May 20 - Stock Titan

May 16, 2025
pulisher
May 16, 2025

Biotech Company Makes Bold Leap into AI: Bionoid Pharma Rebrands as AI Maverick Intel - Stock Titan

May 16, 2025
pulisher
May 15, 2025

HOPE Therapeutics Lands $7.8M Deal to Build National Mental Health Network with Ketamine Treatment Centers - Stock Titan

May 15, 2025
pulisher
May 15, 2025

Regeneron Secures Massive $407M Victory: Jury Finds Amgen Guilty of Illegal PCSK9 Drug Bundling Scheme - Stock Titan

May 15, 2025
pulisher
May 13, 2025

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan

May 13, 2025
pulisher
May 13, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics - Stock Titan

May 13, 2025
pulisher
May 12, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - Stock Titan

May 12, 2025
pulisher
May 09, 2025

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - Stock Titan

May 09, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - Stock Titan

May 08, 2025
pulisher
May 07, 2025

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT | CYCC Stock News - Stock Titan

May 07, 2025
pulisher
May 06, 2025

NRXP Reveals Major Mental Health Expansion Plans at Exclusive Mar-A-Lago Investor Event - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Citius Pharmaceuticals Reveals Growth Strategy at Major Jefferies Healthcare Conference - Stock Titan

May 05, 2025
pulisher
May 02, 2025

Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan

May 02, 2025
pulisher
Apr 30, 2025

Generic Percocet Launch: Elite Pharmaceuticals Targets $317M Pain Management Market - Stock Titan

Apr 30, 2025
pulisher
Apr 29, 2025

Trump Executive Order Validates Petros' AI Technology Platform for Revolutionary Drug Access Reform - Stock Titan

Apr 29, 2025
pulisher
Apr 28, 2025

Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package - Stock Titan

Apr 28, 2025
pulisher
Apr 24, 2025

Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

X4 Pharmaceuticals Strengthens Team with 450,000 Share Options Grant: Inside the Retention Plan - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

Major UK Retail Breakthrough: Sonoma's Natural Acne Treatment to Roll Out Across 1,200 Leading Pharmacies - Stock Titan

Apr 22, 2025
pulisher
Apr 21, 2025

Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan

Apr 21, 2025
pulisher
Apr 17, 2025

Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan

Apr 17, 2025
pulisher
Apr 16, 2025

Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan

Apr 16, 2025
pulisher
Apr 15, 2025

Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga

Apr 14, 2025
pulisher
Apr 11, 2025

Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan

Apr 11, 2025
pulisher
Apr 11, 2025

Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Keros Eyes Potential Sale: Board Weighs Strategic Options Amid Investor Interest - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan

Apr 09, 2025
pulisher
Apr 08, 2025

Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan

Apr 08, 2025
pulisher
Apr 04, 2025

Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan

Apr 04, 2025
pulisher
Apr 03, 2025

Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan

Apr 03, 2025
pulisher
Apr 03, 2025

Dogwood Therapeutics Saves Nasdaq Status: $17.5M Cash, Zero Debt After Major Financial Overhaul - Stock Titan

Apr 03, 2025
pulisher
Apr 02, 2025

Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Exclusive: ANI Pharmaceuticals CEO Reveals Growth Strategy at Major Ophthalmology Conference - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan

Mar 28, 2025
pulisher
Mar 27, 2025

aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan

Mar 25, 2025
pulisher
Mar 23, 2025

$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan

Mar 23, 2025

Titan Pharmaceuticals Inc De (TTNP) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.57
price up icon 0.37%
$35.91
price up icon 0.13%
$21.05
price up icon 2.14%
$100.34
price up icon 0.90%
$106.41
price down icon 0.33%
biotechnology ONC
$242.46
price up icon 0.52%
大文字化:     |  ボリューム (24 時間):